Anastrozole 1 - Genetic Pharmaceuticals

First introduced in 1995, anastrozole was developed by Zeneca as a third-generation aromatase inhibitor, offering more targeted estrogen control. It quickly became a frontline option for hormone-sensitive breast cancer in postmenopausal women. The pivotal ATAC trial, initiated in Rome and involving thousands of patients, demonstrated its clear benefits over tamoxifen. Once results were published in 2002, medical guidelines began shifting in favor of anastrozole, securing its place in modern oncology.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Anastrozole 1 by Genetic Pharmaceuticals, consult with your doctor or healthcare professional.